drugset / Trial / NCT05648019
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
Phase 2
Recruiting
40 enrolled
KK Women's and Children's Hospital
Singapore General Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to describe feasibility of delivering point-of-care manufactured CD19-directed CAR T-cell therapy to patients with relapsed/ refractory B-lineage leukaemia/ lymphoma.
Timeline
- Start
- 2022-03-15
- Primary completion
- 2025-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-CD19 CAR-T cells | Cell therapy | 200000 cells/kg | — |
| Subject | anti-CD19 CAR-T cells | Cell therapy | 5e+06 cells/kg | — |